Role of Goserelin in Combination with Endocrine Therapy for the Treatment of Advanced Breast Cancer in Premenopausal Women Positive for Hormone ...
Original Article
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS Volume 00, Number 00, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/cbr.2012.1436
Role of Goserelin in Combination with Endocrine Therapy for the Treatment of Advanced Breast Cancer in Premenopausal Women Positive for Hormone Receptor: A Retrospective Matched Case–Control Study Sangang Wu,1,* Qun Li,2,3,* Yuliang Zhu,2,4,* Jiayuan Sun,2,3 Fengyan Li,2,3 Huanxin Lin,2,3 Xunxing Guan,2,3 and Zhenyu He2,3
Abstract
Objective: This research was to investigate the role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptors. Methods: We retrospectively analyzed 40 patients as the treatment group with advanced breast cancer who, were positive for hormone receptors, received goserelin in combination with endocrine therapy and 40 patients as the control group received endocrine therapy alone, matched for age, gender, receptor status, and tumor stage. Results: The median period of follow-up was 38.9 months. The response status at 6 months, the overall clinical benefit rate was 87.5% and 70.0% in the treatment group and control group, respectively. The mean progressionfree survival (PFS) in the treatment group and control group was 27.9 and 16.9 months, respectively. The 1-, 2-, and 3-year PFS rates were 87.5%, 66.2%, and 49.7%, respectively, in the treatment group and 59.2%, 38.8%, and 35.3%, respectively, in the control group ( p = 0.076). The 1-, 2-, and 3-year overall survival (OS) rates were 100%, 87.2%, and 76.6%, respectively, in the treatment group and 90.0%, 74.2%, and 55.8%, respectively, in the control group ( p = 0.048). For the treatment group with age
